🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →
Browsing Tag

Aurora-INL

1 post
Oklo’s Aurora-INL advanced nuclear project is moving toward a 2028 deployment target as its $3 billion cash position and $8.5 billion valuation raise the execution stakes.
Read More

Oklo Q2 2026: $3bn cash backs Aurora-INL as $8.5bn valuation raises execution test

Oklo has accumulated more than $3 billion of cash and marketable securities while advancing its first Aurora powerhouse toward a 2028 deployment target. The balance sheet reduces near-term financing pressure, but only $1.21 million of second-quarter revenue and an $8.5 billion market value leave investors paying primarily for future nuclear execution rather than current operating earnings.